Report of three cases of herpes zoster during treatment with natalizumab

CNS Neuroscience and Therapeutics

Volumn 19, Issue 4, 2013, Pages 280-281

  Fragoso, Yara Dadalti ^a,b   Brooks, Joseph Bruno Bidin ^a,b   Gomes, Sidney ^c   de Oliveira, Francisco Tomaz Meneses ^c   Gama, Paulo Diniz da ^d  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^b Reference Center for Multiple Sclerosis for the Coastal Region of the State of Sao Paulo   (Brazil)

^c HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA4 INTEGRIN; BETA INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN G4; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; CASE REPORT; CELL ADHESION; DISABILITY; ENDOTHELIUM CELL; FEMALE; FOOD AND DRUG ADMINISTRATION; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; LETTER; MALE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84875585075     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12067     Document Type: Letter

References (10)

1. Stephenson JJ, Kern DM, Agarwal SS, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study. Health Qual Life Outcomes 2012;10:155.
2. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-689.
3. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880.
4. Shenoy ES, Mylonakis E, Hurtado RM, Venna N. Natalizumab and HSV meningitis. J Neurovirol 2011;17:288-290.
5. Kwiatkowski A, Gallois J, Bilbault N, Calais G, Mackowiak A, Hautecoeur P. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012;18:909-911.
6. Cohen JA, Barkof F, Comi G, TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
7. McDonagh M. Drug class review: Disease-modifying drugs for multiple sclerosis: Single drug addendum: Fingolimod: Final Original Report. Portland (OR): Oregon Health & Amp; Science University, 2011.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology (Cleveland) 1983;33:1444-1452.
9. Mustapic Z, Basic-Jukic N, Kes P, et al. Varicella zoster infection in renal transplant recipients: Prevalence, complications and outcome. Kidney Blood Press Res. 2011;34:382-386.
10. Scheiss N, Zong J, Hayward G, Calabresi P, et al. Reactivation of herpes virus in multiple sclerosis patients on natalizumab therapy [P03.163]. Poster presentation, April 29, 2009 at the American Academy of Neurology Congress.